May 11, 2022

Additional Cholesterol-Lowering Drugs for Patients at High CVD Risk

Current guidelines use LDL cholesterol levels as the primary measure to determine whether ezetimibe and/or ezetimibe and proprotein convertase subtilisin/kexin 9 inhibitors should be added to statin therapy for patients with cardiovascular disease (CVD). An international panel now suggests the emphasis should be on lowering cardiovascular risk instead, which means that patients at high risk should receive extra drugs. Read more.


Paxlovid Fell Short in Protecting Adults From COVID-19 Exposure

Paxlovid has been proven effective for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients aged 12 years or older who are at high risk for progression to severe illness. A study using the antiviral therapy did not meet its primary endpoint in a trial looking at prevention in adults whose household contacts tested positive for infection from SARS-CoV-2. Read more.

When Is Nonoperative Treatment of Appendicitis Less Likely Effective?

When possible, in cases of uncomplicated appendicitis, a nonoperative approach using antibiotic therapy is now preferred. But why does that sometimes work in children but not others? A new study in the Journal of the American Medical Network Open sought to answer that question by listing factors that appear to affect the outcomes. Learn more about the results of this study.


Most U.S. Children, Fewer Older Adults, Had COVID-19

While most people in the United States—at least 52% overall—have been infected with SARS-CoV-2, those numbers are slightly skewed by the high percentage of children (around 75%) who have had COVID-19. Only about a third of adults aged 65 years and older have evidence of past infection with the virus. Learn more about what the CDC reported on these statistics.

Facebook   Twitter   USP Google App   USP itunes App
U.S. Pharmacist
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -